Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

NCT02739633 is registered in ClinicalTrials.gov with Samyang Biopharmaceuticals Corporation as lead sponsor.

NCT NCT02739633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02739633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Samyang Biopharmaceuticals Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
December 31, 2019
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic adenocarcinoma of the pancreas, recurrent adenocarcinoma of the pancreas